NEW YORK (GenomeWeb News) – Bayer today said that its Bayer HealthCare business has joined the non-profit Structural Genomics Consortium.

Bayer will provide funding to the consortium to accelerate drug research in the areas of protein science and epigenetics. In addition, it will collaborate with the consortium on research projects to identify small molecules that can interfere with protein activity involved in epigenetic control. Bayer also said that ti will provide a subset of its compound library to the SGC for screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.